1,754 Shares in Neurocrine Biosciences, Inc. $NBIX Acquired by International Assets Investment Management LLC

International Assets Investment Management LLC bought a new position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 1,754 shares of the company’s stock, valued at approximately $220,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. IFP Advisors Inc lifted its holdings in shares of Neurocrine Biosciences by 4.2% during the second quarter. IFP Advisors Inc now owns 2,172 shares of the company’s stock worth $273,000 after buying an additional 88 shares during the last quarter. DE Burlo Group Inc. boosted its position in shares of Neurocrine Biosciences by 2.2% in the first quarter. DE Burlo Group Inc. now owns 4,717 shares of the company’s stock valued at $522,000 after acquiring an additional 100 shares during the period. Central Pacific Bank Trust Division boosted its position in shares of Neurocrine Biosciences by 6.2% in the second quarter. Central Pacific Bank Trust Division now owns 1,725 shares of the company’s stock valued at $217,000 after acquiring an additional 100 shares during the period. Nissay Asset Management Corp Japan ADV boosted its position in shares of Neurocrine Biosciences by 0.9% in the first quarter. Nissay Asset Management Corp Japan ADV now owns 12,293 shares of the company’s stock valued at $1,360,000 after acquiring an additional 107 shares during the period. Finally, Sowell Financial Services LLC boosted its position in shares of Neurocrine Biosciences by 2.2% in the second quarter. Sowell Financial Services LLC now owns 4,893 shares of the company’s stock valued at $615,000 after acquiring an additional 107 shares during the period. 92.59% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on NBIX shares. Needham & Company LLC increased their price objective on Neurocrine Biosciences from $161.00 to $170.00 and gave the company a “buy” rating in a research report on Monday, September 22nd. Wedbush reissued an “outperform” rating on shares of Neurocrine Biosciences in a research report on Monday, September 22nd. Stifel Nicolaus increased their price objective on Neurocrine Biosciences from $166.00 to $174.00 and gave the company a “buy” rating in a research report on Thursday, July 31st. Weiss Ratings reissued a “hold (c+)” rating on shares of Neurocrine Biosciences in a research report on Wednesday, October 8th. Finally, Guggenheim raised their target price on Neurocrine Biosciences from $165.00 to $175.00 and gave the stock a “buy” rating in a research report on Friday, August 1st. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $164.32.

Insider Activity

In other Neurocrine Biosciences news, Director Kevin Charles Gorman sold 106,322 shares of Neurocrine Biosciences stock in a transaction on Thursday, August 7th. The stock was sold at an average price of $126.41, for a total transaction of $13,440,164.02. Following the completion of the transaction, the director directly owned 514,596 shares of the company’s stock, valued at approximately $65,050,080.36. This trade represents a 17.12% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 4.80% of the company’s stock.

Neurocrine Biosciences Price Performance

Neurocrine Biosciences stock opened at $143.67 on Friday. The firm has a market capitalization of $14.25 billion, a P/E ratio of 42.51, a P/E/G ratio of 1.00 and a beta of 0.21. The stock has a fifty day moving average price of $139.71 and a two-hundred day moving average price of $127.13. Neurocrine Biosciences, Inc. has a 52-week low of $84.23 and a 52-week high of $154.61.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its quarterly earnings data on Wednesday, July 30th. The company reported $1.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.98 by $0.08. The company had revenue of $687.50 million during the quarter, compared to analysts’ expectations of $653.09 million. Neurocrine Biosciences had a return on equity of 13.22% and a net margin of 13.88%.The business’s revenue was up 16.5% on a year-over-year basis. During the same period last year, the business earned $1.63 earnings per share. On average, equities research analysts predict that Neurocrine Biosciences, Inc. will post 4.28 EPS for the current fiscal year.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.